chr3-45491732-G-A

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_015340.4(LARS2):​c.1455G>A​(p.Ala485Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.922 in 1,614,084 control chromosomes in the GnomAD database, including 697,058 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.80 ( 52827 hom., cov: 32)
Exomes 𝑓: 0.93 ( 644231 hom. )

Consequence

LARS2
NM_015340.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:8

Conservation

PhyloP100: -3.83

Publications

24 publications found
Variant links:
Genes affected
LARS2 (HGNC:17095): (leucyl-tRNA synthetase 2, mitochondrial) This gene encodes a class 1 aminoacyl-tRNA synthetase, mitochondrial leucyl-tRNA synthetase. Each of the twenty aminoacyl-tRNA synthetases catalyzes the aminoacylation of a specific tRNA or tRNA isoaccepting family with the cognate amino acid. [provided by RefSeq, Jul 2008]
LARS2-AS1 (HGNC:40796): (LARS2 antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BP6
Variant 3-45491732-G-A is Benign according to our data. Variant chr3-45491732-G-A is described in ClinVar as Benign. ClinVar VariationId is 226693.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-3.83 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.953 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
LARS2NM_015340.4 linkc.1455G>A p.Ala485Ala synonymous_variant Exon 13 of 22 ENST00000645846.2 NP_056155.1 Q15031

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
LARS2ENST00000645846.2 linkc.1455G>A p.Ala485Ala synonymous_variant Exon 13 of 22 NM_015340.4 ENSP00000495093.1 Q15031

Frequencies

GnomAD3 genomes
AF:
0.799
AC:
121611
AN:
152118
Hom.:
52811
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.422
Gnomad AMI
AF:
0.986
Gnomad AMR
AF:
0.905
Gnomad ASJ
AF:
0.889
Gnomad EAS
AF:
0.976
Gnomad SAS
AF:
0.920
Gnomad FIN
AF:
0.976
Gnomad MID
AF:
0.861
Gnomad NFE
AF:
0.948
Gnomad OTH
AF:
0.826
GnomAD2 exomes
AF:
0.912
AC:
229280
AN:
251372
AF XY:
0.921
show subpopulations
Gnomad AFR exome
AF:
0.413
Gnomad AMR exome
AF:
0.946
Gnomad ASJ exome
AF:
0.885
Gnomad EAS exome
AF:
0.978
Gnomad FIN exome
AF:
0.973
Gnomad NFE exome
AF:
0.948
Gnomad OTH exome
AF:
0.918
GnomAD4 exome
AF:
0.935
AC:
1366633
AN:
1461848
Hom.:
644231
Cov.:
59
AF XY:
0.936
AC XY:
680828
AN XY:
727228
show subpopulations
African (AFR)
AF:
0.403
AC:
13477
AN:
33478
American (AMR)
AF:
0.940
AC:
42048
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.882
AC:
23048
AN:
26134
East Asian (EAS)
AF:
0.978
AC:
38807
AN:
39700
South Asian (SAS)
AF:
0.929
AC:
80148
AN:
86258
European-Finnish (FIN)
AF:
0.971
AC:
51867
AN:
53420
Middle Eastern (MID)
AF:
0.885
AC:
5103
AN:
5768
European-Non Finnish (NFE)
AF:
0.951
AC:
1057310
AN:
1111974
Other (OTH)
AF:
0.908
AC:
54825
AN:
60392
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.476
Heterozygous variant carriers
0
4559
9118
13678
18237
22796
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
21514
43028
64542
86056
107570
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.799
AC:
121660
AN:
152236
Hom.:
52827
Cov.:
32
AF XY:
0.805
AC XY:
59958
AN XY:
74456
show subpopulations
African (AFR)
AF:
0.421
AC:
17487
AN:
41496
American (AMR)
AF:
0.905
AC:
13852
AN:
15310
Ashkenazi Jewish (ASJ)
AF:
0.889
AC:
3088
AN:
3472
East Asian (EAS)
AF:
0.976
AC:
5058
AN:
5184
South Asian (SAS)
AF:
0.920
AC:
4434
AN:
4820
European-Finnish (FIN)
AF:
0.976
AC:
10368
AN:
10626
Middle Eastern (MID)
AF:
0.864
AC:
254
AN:
294
European-Non Finnish (NFE)
AF:
0.948
AC:
64478
AN:
68018
Other (OTH)
AF:
0.828
AC:
1742
AN:
2104
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
834
1669
2503
3338
4172
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
836
1672
2508
3344
4180
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.867
Hom.:
27464
Bravo
AF:
0.775
Asia WGS
AF:
0.915
AC:
3180
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
Nov 24, 2014
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Ala485Ala in exon 13 of LARS2: This variant is not expected to have clinical sig nificance because it does not alter an amino acid residue and is not located wit hin the splice consensus sequence. It has been identified in 44.0% (1938/4406) o f African American chromosomes from a broad population by the NHLBI Exome Sequen cing Project (http://evs.gs.washington.edu/EVS; dbSNP rs2128361). -

Dec 02, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Feb 16, 2016
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Perrault syndrome 4 Benign:1
Aug 19, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome Benign:1
Aug 19, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.88
CADD
Benign
0.037
DANN
Benign
0.65
PhyloP100
-3.8
Mutation Taster
=99/1
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2128361; hg19: chr3-45533224; COSMIC: COSV55528821; API